Cargando…

Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial

IMPORTANCE: Clinical outcomes for glioblastoma remain poor. Treatment with immune checkpoint blockade has shown benefits in many cancer types. To our knowledge, data from a randomized phase 3 clinical trial evaluating a programmed death-1 (PD-1) inhibitor therapy for glioblastoma have not been repor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Reardon, David A., Brandes, Alba A., Omuro, Antonio, Mulholland, Paul, Lim, Michael, Wick, Antje, Baehring, Joachim, Ahluwalia, Manmeet S., Roth, Patrick, Bähr, Oliver, Phuphanich, Surasak, Sepulveda, Juan Manuel, De Souza, Paul, Sahebjam, Solmaz, Carleton, Michael, Tatsuoka, Kay, Taitt, Corina, Zwirtes, Ricardo, Sampson, John, Weller, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2020
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7243167/ https://www.ncbi.nlm.nih.gov/pubmed/32437507 http://dx.doi.org/10.1001/jamaoncol.2020.1024

Ejemplares similares

Nivolumab plus radiotherapy with or without temozolomide in newly diagnosed glioblastoma: Results from exploratory phase I cohorts of CheckMate 143
por: Omuro, Antonio, et al.
Publicado: (2022)

Recurrent glioma clinical trial, CheckMate-143: the game is not over yet
por: Filley, Anna C., et al.
Publicado: (2017)

Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter
por: Lim, Michael, et al.
Publicado: (2022)

Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial
por: Omuro, Antonio, et al.
Publicado: (2022)

CheckMATE tutorial
por: Kim, Jong Soo, et al.
Publicado: (2021)

A colour symphony ; Checkmate.
por: Bliss, Arthur, Sir, 1891-1975
Publicado: (1987)

Implementation of ML searches in CheckMATE
por: Rolbiecki, Krzysztof
Publicado: (2022)

Recent developments in CheckMATE 2
por: Wang, Zeren Simon
Publicado: (2021)

Checkmate to CHK1 in T-cell ALL?
por: Sarmento, Leonor M., et al.
Publicado: (2015)

Checkpoint Inhibitors in Checkmating Rare Cancers
por: Srinivas, Sujay, et al.
Publicado: (2021)

Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial
por: Naumann, R. Wendel, et al.
Publicado: (2019)

Implementation of multi-bin searches in CheckMATE
por: Lara Perez, Iñaki
Publicado: (2022)

Checkmate to deliberate practice: the case of Magnus Carlsen
por: Gobet, Fernand, et al.
Publicado: (2014)

Targeting Phosphatases and Kinases: How to Checkmate Cancer
por: Turdo, Alice, et al.
Publicado: (2021)

Check(point) or checkmate for acute myeloid leukemia?
por: Niyongere, Sandrine, et al.
Publicado: (2021)

Immunotherapy: an emerging modality to checkmate brain metastasis
por: Ahmad, Aatiya, et al.
Publicado: (2023)

From CheckMate 227 to CheckMate 9LA: rethinking the status of chemotherapy in the immunotherapy era—chemo-free or chemo-reform?
por: Deng, Haiyi, et al.
Publicado: (2021)

Combination therapy to checkmate Glioblastoma: clinical challenges and advances
por: Ghosh, Debarati, et al.
Publicado: (2018)

Myasthenia Gravis and COVID-19 – A Clinical Checkmate
por: Sivapurapu, Vijayalakshmi, et al.
Publicado: (2021)

Theranostic Potential of Adaptive Cold Atmospheric Plasma with Temozolomide to Checkmate Glioblastoma: An In Vitro Study
por: Soni, Vikas, et al.
Publicado: (2022)

Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032
por: Ready, Neal, et al.
Publicado: (2018)

Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204)
por: Tawbi, Hussein A, et al.
Publicado: (2021)

EWino searches in CheckMate and $(g-2)_\mu$ in the MSSM
por: Chakraborti, Manimala
Publicado: (2021)

Health-related quality of life results from the phase III CheckMate 067 study
por: Schadendorf, Dirk, et al.
Publicado: (2017)

Long-term Remission Over Six Years for a Patient with Recurrent Glioblastoma Treated with Cediranib/Lomustine
por: Drazin, Doniel, et al.
Publicado: (2016)

Acquired resistance to anti-PD1 therapy: checkmate to checkpoint blockade?
por: O’Donnell, Jake S., et al.
Publicado: (2016)

Modeling YAP fusions: a paradigm for investigating rare cancers?
por: Sahebjam, Solmaz, et al.
Publicado: (2022)

Post-irradiation lumbosacral radiculopathy associated with multiple cavernous malformations of the cauda equina: Case report and review of the literature
por: Drazin, Doniel, et al.
Publicado: (2017)

Vitamin D Intake and its Protective Role in Multiple Sclerosis: The Checkmate to Survivin?
por: Mormile, Raffaella
Publicado: (2016)

CHEK2 Germline Variants in Cancer Predisposition: Stalemate Rather than Checkmate
por: Stolarova, Lenka, et al.
Publicado: (2020)

Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451
por: Owonikoko, Taofeek K., et al.
Publicado: (2021)

CheckMate 214 trial: Immune checkpoint regulators for advanced renal cell carcinoma
por: Jena, Rahul
Publicado: (2020)

A Potential Checkmate to Lead: Bismuth in Organometal Halide Perovskites, Structure, Properties, and Applications
por: Attique, Sanam, et al.
Publicado: (2020)

Different interpretations of the CheckMate-227 trial in non-small-cell lung cancer
por: Su, Zheng
Publicado: (2020)

Contents of Volume 143
Publicado: (2010)

TRLS-01. RADIOSURGERY FOLLOWED BY TUMOR TREATING FIELDS (TTFIELDS) FOR BRAIN METASTASES (1–10) FROM NSCLC IN THE PHASE 3 METIS TRIAL
por: Mehta, Minesh, et al.
Publicado: (2019)

CLRM-10 METIS (EF-25): A PIVOTAL, RANDOMIZED CONTROLLED STUDY OF TUMOR TREATING FIELDS IN PATIENTS WITH 1–10 BRAIN METASTASES FROM NON-SMALL CELL LUNG CANCER
por: Mehta, Minesh, et al.
Publicado: (2022)

Treatment-free survival over extended follow-up of patients with advanced melanoma treated with immune checkpoint inhibitors in CheckMate 067
por: Regan, Meredith M, et al.
Publicado: (2021)

30. RADIOSURGERY FOLLOWED BY TUMOR TREATING FIELDS FOR BRAIN METASTASES (1–10) FROM NSCLC IN THE PHASE 3 METIS TRIAL
por: Mehta, Minesh P, et al.
Publicado: (2020)

CheckMate-722: The Rise and Fall of Nivolumab with Chemotherapy in TKI-Refractory EGFR-Mutant NSCLC
por: Lee, Alexandria T M, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_pupln43hsh52339jm4o67jvhpn